Zepbound, a drug used to help patients lose weight and manage diabetes, may also help those with heart failure, a new trial shows.

Research shows that 1 in 8 adults in the US has used one of the popular GLP-1 medications, most of them trying to manage chronic conditions such as diabetes and heart disease and others to help them lose weight.

Weight-loss drug makers are directly targeting employers in a campaign to expand health insurance coverage of their popular, but pricey, medications.

On a spring day this year, the New Jersey State Policemen’s Benevolent Association received three unusual visitors: pharmaceutical representatives from Eli Lilly.Lilly’s reps presented a slide deck that laid out data on the effectiveness of Lilly’s weight-loss drug Zepbound.

A drug used to help patients lose weight and manage diabetes may also help those with heart failure, an international clinical trial shows.

A survey by consulting firm Mercer shows that close to half of U.S. companies with more than 500 employees now cover drugs such as Wegovy, Ozempic, and Zepbound.

GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably heard of them under brand names like Ozempi​​c® and Wegovy® (semaglutide) or Monjouro and Zepbound (tirzepatide).